TR200000875T2 - Osteoblast-spesifik mitojenler ve sözkonusu bileşikleri içeren ilaçlar. - Google Patents

Osteoblast-spesifik mitojenler ve sözkonusu bileşikleri içeren ilaçlar.

Info

Publication number
TR200000875T2
TR200000875T2 TR2000/00875T TR200000875T TR200000875T2 TR 200000875 T2 TR200000875 T2 TR 200000875T2 TR 2000/00875 T TR2000/00875 T TR 2000/00875T TR 200000875 T TR200000875 T TR 200000875T TR 200000875 T2 TR200000875 T2 TR 200000875T2
Authority
TR
Turkey
Prior art keywords
compounds
question
drugs containing
specific mitogens
containing osteoblast
Prior art date
Application number
TR2000/00875T
Other languages
English (en)
Inventor
Esswein Angelika
Kling Lothar
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of TR200000875T2 publication Critical patent/TR200000875T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bulus, R =6-24 karbon atomuna sahip alkil, alkenil veya alkinil; n=0-12; X=oksijen veya NH oldugu formül (I)'in bilesiklerine; ve bunlarin, genel formül (I)'in bilesiklerini vermek üzere, canli organizmada metabolizmasi mümkün olan, fizyolojik açidan güvenli tuzlar, esterler, optik açidan aktif formlar, rasematlar ve türevlerine, bunlari hazirlama yöntemlerine ve sözkonusu bilesikleri içeren, kemik metabolizmasi bozukluklarinin tedavisinde kullanilan ilaçlara yöneliktir.
TR2000/00875T 1997-10-02 1998-09-30 Osteoblast-spesifik mitojenler ve sözkonusu bileşikleri içeren ilaçlar. TR200000875T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97117124A EP0906759A1 (de) 1997-10-02 1997-10-02 Neue Osteoblastenspezifische Mitogene: Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
TR200000875T2 true TR200000875T2 (tr) 2000-11-21

Family

ID=8227430

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00875T TR200000875T2 (tr) 1997-10-02 1998-09-30 Osteoblast-spesifik mitojenler ve sözkonusu bileşikleri içeren ilaçlar.

Country Status (16)

Country Link
US (1) US6197759B1 (tr)
EP (2) EP0906759A1 (tr)
JP (2) JP2001518511A (tr)
KR (1) KR100392207B1 (tr)
CN (1) CN1191070C (tr)
AR (1) AR013538A1 (tr)
AT (1) ATE232103T1 (tr)
AU (1) AU738479B2 (tr)
BR (1) BR9813020A (tr)
CA (1) CA2304821C (tr)
DE (1) DE69811253T2 (tr)
DK (1) DK1019062T3 (tr)
ES (1) ES2191350T3 (tr)
TR (1) TR200000875T2 (tr)
WO (1) WO1999017781A1 (tr)
ZA (1) ZA988952B (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
US7384652B2 (en) 2002-06-24 2008-06-10 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Complexed-acidic-phospholipid-collagen composites for bone induction
KR100789323B1 (ko) * 2005-07-20 2007-12-28 주식회사 엔지켐 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체
US20100266691A1 (en) * 2009-04-15 2010-10-21 Battelle Memorial Institute Agents and Methods to Stimulate Bone Healing
CN113842504B (zh) * 2021-09-22 2022-12-09 苏州大学附属第二医院 一种用于骨再生的多功能电纺支架的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164560A (en) 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
PL151315B1 (pl) * 1987-04-17 1990-08-31 Sposób wytwarzania nowych związków powierzchniowo czynnych
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
DE69213739T2 (de) 1991-06-21 1997-02-20 Genetics Institute, Inc., Cambridge, Mass. Osteogene proteine enthaltende arzneimittel
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
WO1993020859A1 (en) 1992-04-20 1993-10-28 Board Of Regents Of The University Of Washington Sustained release compositions for delivery of growth factors
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
CA2119090A1 (en) 1993-03-26 1994-09-27 Wayne R. Gombotz Compositions for controlled release of biologically active tgf-.beta.
ATE169924T1 (de) * 1993-05-18 1998-09-15 Takeda Chemical Industries Ltd Benzopyran-derivate und ihre verwendung
ES2065855B1 (es) * 1993-05-31 1995-09-01 Menarini Lab Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
DE19544635A1 (de) * 1995-11-30 1997-06-05 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1019062A1 (en) 2000-07-19
ATE232103T1 (de) 2003-02-15
WO1999017781A1 (en) 1999-04-15
EP1019062B1 (en) 2003-02-05
DK1019062T3 (da) 2003-05-26
ES2191350T3 (es) 2003-09-01
CA2304821C (en) 2005-08-02
DE69811253T2 (de) 2003-12-04
AU1148399A (en) 1999-04-27
JP2001518511A (ja) 2001-10-16
AU738479B2 (en) 2001-09-20
ZA988952B (en) 2000-04-03
BR9813020A (pt) 2000-08-15
KR20010030822A (ko) 2001-04-16
US6197759B1 (en) 2001-03-06
CA2304821A1 (en) 1999-04-15
CN1191070C (zh) 2005-03-02
DE69811253D1 (de) 2003-03-13
EP0906759A1 (de) 1999-04-07
JP2004217667A (ja) 2004-08-05
CN1271289A (zh) 2000-10-25
KR100392207B1 (ko) 2003-07-23
AR013538A1 (es) 2000-12-27

Similar Documents

Publication Publication Date Title
FI885569A0 (fi) Vattenloesliga kamptothecinanaloger.
DK0430045T3 (da) Ascorbinsyretocopherylphosphatdiestere til hæmning af Maillards reaktion
AU2330202A (en) Treatment of statin side effects
NO2011018I1 (no) Eribulin og farmasøytisk akseptable salter derav
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
DE60043318D1 (de) Synergistische kombination von pumafentrine und salmeterol
HU0000921D0 (en) Thyromimetic antiobesity agents
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
DK0756595T3 (da) Substituerede 1,3-oxathiolaner med antivirale egenskaber
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
MX9306049A (es) Dinucleotido de nicotinamida-ademina y fosfato de dinucleotido de nicotinamida-adenina como farmacos para tratar la enfermedad de alzheimer.
TR200000875T2 (tr) Osteoblast-spesifik mitojenler ve sözkonusu bileşikleri içeren ilaçlar.
PT783495E (pt) Derivados de quinoxalina uteis em terapia
ATE234086T1 (de) Creatine derivate für asthma
AU670491C (en) Pharmaceutical for the treatment of skin disorders
DE60006379D1 (de) Vitamin d-analogen und ihre pharmazeutische verwendung
HUP9801985A2 (hu) Cisztinszármazékok alkalmazása restenózis gyógyítására használható gyógyszerkészítmények előállítására
DK0814813T3 (da) Anvendelse af penciclovir til behandling af human herpesvirus-8
EP1465616A4 (en) TREATMENT OF SIDE EFFECTS OF STATINE USING URIDINE DERIVATIVES
NO881734D0 (no) Tiadiazolguanidiner og fremgangsmaate for deres fremstilling.